View of Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Return to Article Details Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes Download Download PDF